Effect of Immunomodulatory Therapy With Adalimumab on Endothelial Function in Patients With Moderate to Severe Psoriasis
Phase of Trial: Phase II
Latest Information Update: 29 Dec 2016
At a glance
- Drugs Adalimumab (Primary)
- Indications Psoriasis
- Focus Pharmacodynamics
- 19 Apr 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 27 Mar 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 13 May 2013 Planned end date changed from 1 Sep 2014 to 1 Sep 2015 as reported by ClinicalTrials.gov.